These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6370127)

  • 1. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime in normal and uremic subjects.
    Leroy A; Leguy F; Borsa F; Spencer GR; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of decreased renal function on the pharmacokinetics of ceftazidime.
    Ackerman BH; Ross J; Tofte RW; Rotschafer JC
    Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of moxalactam in patients with renal insufficiency.
    Lam M; Manion CV; Czerwinski AW
    Antimicrob Agents Chemother; 1981 Mar; 19(3):461-4. PubMed ID: 6454383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():241-5. PubMed ID: 6352626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefsulodin pharmacokinetics in patients with various degrees of renal function.
    Matzke GR; Keane WF
    Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
    Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA
    Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.